Generation of inhibitors targeting general control nonderepressible 2 (GCN2) as a novel targeted therapy for ovarian cancer
Drs. Tracy McGaha and Robert Rottapel, Senior Scientists at UHN’s Princess Margaret Cancer Centre, along with their teams were awarded funding to support the discovery and development of small molecule inhibitors of GCN2 as a novel therapeutic mechanism for targeted therapy of ovarian cancer.
Ovarian cancer is the leading cause of death from gynecologic cancer in Canada with a 5-year survival of only 44%, underscoring the need for novel treatment strategies beyond conventional chemotherapy alone. GCN2 is a key factor that controls the cellular stress response in conditions of low amino acid availability; the McGaha/Rottapel team has identified GCN2 as a key contributor to suppression of inflammatory anti-tumor...Read More